

S 3094

PRICED Act

Congress: 114 (2015–2017, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jun 23, 2016

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jun 23, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/senate-bill/3094>

Sponsor

Name: Sen. Brown, Sherrod [D-OH]

Party: Democratic • **State:** OH • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. McCain, John [R-AZ]	R · AZ		Jun 23, 2016

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jun 23, 2016

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
114 HR 5573	Identical bill	Jun 23, 2016: Referred to the House Committee on Energy and Commerce.

Summary (as of Jun 23, 2016)

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.

This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Actions Timeline

• **Jun 23, 2016:** Introduced in Senate

Generated by LegiList — <https://legilist.com> · Public data belongs to the public.

• **Jun 23, 2016:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.